GENE ONLINE|News &
Opinion
Blog

2023-05-10| Special

Novavax, Takeda, and BMS To Cut Employees This Year

by Reed Slater
Share To

With several companies forced to make layoffs last year, 2023 shows few signs of slowing down, with major companies like Novavax, Takeda, and Bristol Myers Squibb announcing plans to cut employees in various areas throughout the U.S. 

Restructuring Novavax as COVID-19 Slows Down

After placing all of its efforts on developing a COVID-19 vaccine over the last few years, Novavax is forced to realign some of its core focuses as its original vaccine struggles to keep pace with the powerhouse vaccines that Moderna and Pfizer have released. The company is placing particular emphasis on an updated and competitive version of Nuvaxovid, the company’s protein-based vaccine. 

Last year, Novavax recorded $704 million in revenue in the first quarter due to an increased demand for COVID-19 vaccines. This year, however, the company recorded $81 million in revenue over the course of the same period. 

Although Novavax saw these dropoffs coming, it is still facing serious adversity in the coming year. Novavax said it plans to cut up to 25% of its staff, primarily full-time research and development employees, to make room for future development plans. 

President and CEO at Novavax, John C. Jacobs, said, “Reducing our workforce has been a difficult decision, but we believe it was necessary to better align our infrastructure and scale to the endemic COVID opportunity.”

The huge reduction could result in up to 500 employees losing their jobs. Still, the company has high hopes for the future with a promising combination COVID-19/influenza vaccine currently in Phase 2 clinical trials.

Related Article: 35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway

Takeda and BMS’s Plans Going Forward

The news of Takeda and BMS’s plans to make layoffs came from WARN notices published by New Jersey and Massachusetts government websites. So far, neither company has issued a press release outlining the particular reasons for the layoffs. 

In New Jersey, BMS plans to lay off up to 48 employees from its Princeton location. According to the WARN notice, the layoff could go into effect as soon as the end of this month. Also in New Jersey, Thermo Fisher Scientific announced a Princeton layoff in March that could affect 113 employees. Roche molecular systems also announced a layoff in April that could result in 165 employees losing their jobs. 

Takeda also issued a WARN notice; however, the company issued it in Massachusetts, where a layoff could affect up to 138 employees across four Cambridge locations. Takeda Shire Human Genetics Therapies, Inc., could also lose 48 employees in various locations across Massachusetts. 

As the economic landscaping surrounding the biotech industry changes rapidly, several companies have to adapt to overcome an onslaught of new challenges. With these challenges often come changes, which, unfortunately, this time, will result in hundreds of biotech employees losing their jobs. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Ginkgo Job Cuts Expected to Affect at Least 35% of Workforce, Eliminating Over 400 Jobs
2024-07-02
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top